30,000 Shares in Magenta Therapeutics Inc (MGTA) Purchased by Bollard Group LLC
Bollard Group LLC bought a new position in shares of Magenta Therapeutics Inc (NASDAQ:MGTA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 30,000 shares of the company’s stock, valued at approximately $360,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of MGTA. Point72 Asset Management L.P. acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $109,000. Point72 Hong Kong Ltd acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $109,000. Tiverton Asset Management LLC acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $125,000. Northern Trust Corp acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $179,000. Finally, Dean Capital Investments Management LLC acquired a new stake in shares of Magenta Therapeutics during the second quarter worth $558,000. 30.31% of the stock is owned by institutional investors.
Shares of NASDAQ MGTA opened at $7.17 on Friday. Magenta Therapeutics Inc has a 52 week low of $6.10 and a 52 week high of $16.33.
Separately, Zacks Investment Research upgraded Magenta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Magenta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $19.33.
Magenta Therapeutics Company Profile
Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.
Featured Article: Bond
Want to see what other hedge funds are holding MGTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Magenta Therapeutics Inc (NASDAQ:MGTA).
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.